Background/Aims: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and has the third highest mortality rate among all cancers. MicroRNAs are a class of endogenous, single-stranded short noncoding RNAs. The purpose of this study was to study the role of microRNA-873 in HCC. Methods: The expression of miRNA-873 and tumor suppressor in lung cancer 1 (TSLC1) in HCC tissues and cell lines was detected by real-time quantitative RT-PCR (RT-qPCR) or western blot. A CCK-8 assay was used to examine cell proliferation; flow cytometry was used to assess the cell cycle; the Transwell migration assay was used to test for metastasis. Luciferase assays were performed to assess whether TSLC1 was a novel target of miRNA-873. Results: We showed that miRNA-873 was upregulated in HCC tissues and cell lines compared with the normal control. Knockdown of miRNA-873 inhibited the growth and metastasis of HepG2 and accelerated G1 phase arrest, while overexpression of miRNA-873 had the opposite effect. The dual-luciferase reporter assays revealed that TSLC1 was a novel target of miRNA-873. Further study showed that TSLC1 was decreased in HCC tissues and cell lines. There was a negative correlation between the expression levels of TSLC1 and miRNA-873. The effect of miRNA-873 overexpression was neutralized by TSLC1. We also found that miRNA-873 activated the PI3K/AKT/mTOR signaling pathway and promoted HCC. Conclusions: Our data demonstrated that miRNA-873 promoted HCC progression by targeting TSLC1 and provided a new target for the therapy of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancers in the world and the third most common tumor-related cause of death [1, 2] . Although surgical resection, liver transplantation and interventional therapy have achieved great progress in recent years, ineffective diagnosis, as well as progression and migration, leads to dissatisfactory overall survival. Therefore, it is urgent to study the mechanism of HCC progression and provide an effective therapeutic strategy.
MicroRNAs (miRNAs) are a new class of small non-coding RNAs that regulate gene expression by translational repression or degradation by targeting complementary sequences of mRNAs in the 3ʹ-untranslated region (3ʹ-UTR) [3, 4] . It has been reported in multiple studies that miRNAs are involved in the biology of many tumors, playing roles in cell proliferation, differentiation, motility, apoptosis, angiogenesis and metastasis [5] [6] [7] [8] [9] . In recent years, many miRNAs have been recognized to promote progression of HCC through enhancing oncogene expression or inhibiting tumor suppressor genes [10] [11] [12] . miRNA-873 has been reported to be frequently and aberrantly expressed in many cancers, such as glioblastoma [13] , lung adenocarcinoma [14] , breast cancer [15] and ovarian cancer [16] . miRNA-873 inhibits ER (estrogen receptor)-α activity and cell growth by targeting CDK3, mediating tamoxifen resistance [15] . miRNA-873 is downregulated in glioblastoma, inhibiting cell proliferation, migration and invasion and inducing apoptosis through suppressing the expression of IGF2BP1 [13] . However, it is upregulated in lung adenocarcinoma, acting as an oncogene. The role of miRNA-873 in HCC has not yet been investigated. In this study, we sought to investigate the role miRNA-873 in HCC progression, aiming to provide a deeper understanding of the causal mechanisms of cancer cell invasion and metastasis.
Materials and Methods

Tissues and cell lines
Tumor tissue samples were taken from patients with primary HCC. All the patients underwent curative resection at the First Affiliated Hospital of Nanjing Medical University (Nanjing, China). Written informed consent was obtained from each patient before surgery. This study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University.
Cell lines used in this study included four HCC cell lines (Hep3B, HepG2, SMMC-7721, and Huh-7) and one human normal hepatic cell line (L02). All the cell lines were purchased from the Chinese Academy of Sciences Cell Bank (Shanghai, China). All cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum (HyClone, South Logan, UT, USA), 100 units/mL penicillin and 100 μg/mL streptomycin, incubated at 37 °C in 5% CO 2 .
RNA isolation and real-time quantitative RT-PCR
Total RNA was extracted using TRIzol Reagent (Takara, Dalian, China) according to the manufacturer's protocol. The quality and concentration were detected using a Nanodrop 2000 (NanoDrop Technologies, Massachusetts, USA). RT-qPCR was performed with SYBR Premix ExTaq (TaKaRa) with the ABI Prism 7900HT (Applied Biosystems, Foster City, CA, USA). U6 was used as internal control for mRNA quantification. The relative expression ratio of miR-873 and TSLC1 in each tissue and cell line was calculated using the 2 Cellular Physiology and Biochemistry
Cellular Physiology and Biochemistry
antibody for 2 h at room temperature. After the membrane was washed again with TBST as described previously, proteins were visualized with an enhanced chemiluminescence detection kit according to the manufacturer's recommendations (Beyotime, Nantong, China). Protein levels were calculated relative to GAPDH.
Cell transfection
Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA) was used to perform miRNA transfection according to the manufacturer's protocol. Cells were plated in six-well plates at a density of 1.5×10 5 cells per well the day before transfection. When the cells were in the log phase, an miRNA-873 inhibitor or mimic (Genepharma, Shanghai, China) was added to the well. The medium was replaced after a 6-h incubation period. Cells were harvested 48-72 h later for analysis. For the transfection of TSLC1, lentiviruses overexpressing TSLC1 (lv-TSLC1) and corresponding control lentiviruses (lv-green fluorescent protein) were constructed by Genepharma (Shanghai, China). Cells were plated in six-well plates at a density of 2×10 5 cells per well. When the density reached 30%-40% after incubation, lentiviruses were transfected into HCC cells with a multiplicity of infection of 10. Seventy-two hours after infection, cells were selected for 2 weeks using puromycin (10 μg/mL). The selected cell lines were analyzed for TSLC1 expression and prepared for subsequent experiments.
Luciferase assay
MiRNA targets were predicted using the algorithm TargetScan. Cells (5 ×10 4 ) were seeded in 24-well plates and cultured for 24 h. The TSLC1 reporter luciferase plasmid (100 ng), pGL3-TSLC1, pGL3-TSLC1-mut or control luciferase plasmid, and 5 ng pRL-TK Renilla plasmid (Promega,Madison, WI, USA) were transfected into the cells using Lipofectamine 3000 according to the manufacturer's instructions. Luciferase and Renilla signals were measured 48 h after transfection using a Dual-Luciferase Reporter Assay Kit (Promega) according to the manufacturer's protocol.
CCK-8 assay
The Cell Counting Kit-8 (CCK-8, Dojindo, Kumamoto, Japan) was used in this study. Cells were plated in 96-well plates at a density of 3000 cells/well. Ten microliters of CCK-8 was added to each well at several time points (0, 24, 48, 72 and 96 h). The cells were incubated at 37 °C for 2 hours. The absorbance at 450 nm was measured to generate cell growth curves.
Transwell assay
The migration and invasion assay was performed using Transwell chambers (Corning Incorporated, Corning, NY, USA). For migration, 4×10 4 cells were resuspended in serum-free medium and seeded into a Transwell insert supplemented with DMEM containing 5% serum. After 24-48 h incubation, the cells on the bottom side of the membrane were fixed with 95% alcohol and stained with crystal violet for 20 min at room temperature. Then, the number of cells on the lower side of the filter was counted under a microscope. Each experiment was performed in triplicate. For invasion, Matrigel was applied to the upper surface before the cells were added. The other steps were the same as for the migration assay.
Flow cytometry analysis
A Cell Cycle Detection Kit (Vazyme Biotech, Nanjing, China) was used. Cells were plated in a six-well plate and cultured for 48 h. Then, the cells were collected and fixed with 70% ethanol at 4 °C for more than 6 h and then washed with phosphate-buffered saline (PBS) twice. The staining was carried out with 50 μg/ mL propidium iodide in PBS-Triton X-100 for 30 min at room temperature in the absence of light. Finally, cells were analyzed on a FACSCalibur flow cytometer equipped with CellQuest software (BD Biosciences, New York, NY, USA).
Statistical analysis SPSS 18.0 (SPSS, Chicago, IL, USA) or Prism 5.0 (GraphPad Software, La Jolla, CA, USA) software was used for statistical analyses. The results are presented as the mean ± standard error of the mean. Quantitative and categorical data were subjected to the two-tailed Student's t-test and the χ 2 test, respectively. P < 0.05 was considered statistically significant.
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Results
miRNA-873 is upregulated in HCC and correlates with clinical characteristics
We first detected miRNA-873 expression by qRT-PCR. As shown in Fig. 1A , miRNA-873 was significantly upregulated in three HCC cell lines (Hep3B, HepG2, and SMCC-7721) compared with a normal liver cell line (L02). Furthermore, we detected miRNA-873 expression in HCC tissues. A large increase in miRNA-873 was observed in HCC tissues compared with adjacent non-cancerous tissues (Fig. 1B) . These data demonstrate that miRNA-873 expression was elevated in HCC. We further analyzed the correlation between miRNA-873 expression and clinical parameters in 70 HCC patients. As shown in Table 1 Fig. 2A  and 3A) . HepG2 transfected with miRNA-873 inhibitor showed a decreased cell growth rate and an impaired capacity for migration and invasion. The cell cycle was arrested at G1 (Fig. 2B-D) . Huh7 cells transfected with miRNA-873 mimic showed an increased growth rate and enhanced migration and invasion ability. Cell cycle analysis showed that miRNA-873 accelerated the S phase (Fig. 3B-D ). These data demonstrate that miRNA-873 promotes HCC cell proliferation, migration and invasion.
TSLC1 is a direct target of miR-NA-873 in HCC cells
We found that TSLC1, whose 3'-UTR was complementary to miR-NA-873, could be a potential target of that miRNA (Fig. 4A) . TSLC1 has been reported as a tumor suppressor gene in many tumors, including HCC [17, 18] . We detected the expression of TSLC1 in HCC and found that TSLC1 was significantly decreased in HCC cell lines and tissues (Fig. 4B) . Furthermore, Spearman's correlation analysis showed that TSLC1 mRNA levels were inversely correlated with miRNA-873 levels (Fig. 4C) . To verify their connection, we conducted dual luciferase reporter experiments. The result showed that overexpressed miRNA-873 could significantly suppress the luciferase activity of the wild 3'-UTR of TSLC1 but not the mutant 3'-UTR of TSLC1 (Fig. 4D ). These data demonstrate that miR-NA-873 can directly target TSLC1 and suppress its expression.
TSLC1 rescued the effect of miRNA-873-mediated HCC progression
To determine whether TSLC1 is involved in miRNA-873-regulated HCC cell proliferation, migration, and invasion, we used a lentiviral vector overexpressing TSLC1. Huh7 cells transfected with miRNA-873 mimics were infected with lv-TSLC1. We found that increased TSLC1 could rescue the effect of miRNA-873 mimics on proliferation, migration and invasion in Huh7 cells (Fig. 5A, B, C) . These results indicate that miRNA-873 exerted its accelerative effects in HCC cells by repressing TSLC1. 
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miRNA-873 might promote HCC progression by activating the PI3K/AKT/mTOR
We used western blotting to further explore the potential signaling pathway of miRNA-873-induced HCC progression. The results showed that overexpression of miR-873 could significantly induce PI3K, AKT and mTOR phosphorylation. Conversely, inhibition of miRNA-873 effectively downregulated phosphorylated PI3K, AKT and phosphorylated mTOR (Fig. 6 ). These data demonstrate that miRNA-873 promoted HCC proliferation, migration, and invasion by activating the PI3K/AKT/mTOR signaling pathway.
Discussion
HCC is one of the most common cancers in the world, especially in Asia. Because of the poor overall survival associated with it, new therapies are urgently needed. MicroRNAs have been found to play a dual role in the progression of tumors, including HCC: some act as oncogenes, and some as tumor suppressor genes [19] [20] [21] . For example, miR-155 is upregulated in HCC, promotes cancer cell invasion, and is a predictor of poor survival of hepatocellular carcinoma [22] . Additionally, hepatitis C virus-induced upregulation of miR-155 promotes hepatocarcinogenesis by activating Wnt signaling [23] . In HCC cell lines, microRNA-133a suppresses proliferation, colony formation, migration and invasion and induces cell cycle arrest at the G0/G1 stage, as well as cell apoptosis, indicating a tumor suppression function [24] . miR-34a acts as a tie molecule between p53 and SIRT1 and exerts a tumor suppression effect in HCC by promoting cell apoptosis [25] . Recent studies have shown that miRNA-873 is frequently altered in multiple tumor types and is associated with the pathogenesis and progression of cancer. However, it plays different roles in different tumors. miRNA-873 promotes the proliferation and migration of tumor cells by repressing Src in lung adenocarcinoma [14] but acts as a tumor suppressor in glioblastoma [13] and ovarian cancer [16] . However, little is known about the role of miR-NA-873 in HCC. In the present study, we found that miRNA-873 was significantly increased in HCC tissues and tumor cell lines. miRNA-873 significantly promoted HCC cell proliferation, migration and invasion. 
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Cellular Physiology and Biochemistry TSLC1 has been reported as a tumor suppressor gene that is involved in multiple cellular processes such as cell proliferation, differentiation, migration, and invasion [26, 27] . Tsujiuchi et al. reported that in HCC induced by N-nitrosodiethylamine, the 5' upstream region of TSLC1 was methylated and its expression was reduced [18] . Additionally, some researchers reported that restoration of TSLC1 could effectively inhibit HCC growth [28] . In the present study, we were the first to identify TSLC1 as a direct target of miRNA-873 in HCC cells. TSLC1 expression was decreased in HCC tissues and cell lines. TSLC1 overexpression rescued the effect of miRNA-873-mediated HCC cell proliferation, migration, and invasion. These results suggest that miRNA-873 exerts a tumor-accelerative role in HCC at least partly through repressing TSLC1 expression, and because of the significant decrease of TSLC1 in HCC, it may be an important prognostic indicator for HCC patients. These results together suggest that miRNA-873 could be used as a potential therapeutic target for HCC.
A number of studies have demonstrated that the PI3K/AKT/mTOR signaling pathway is excessively activated in tumors, induces tumorigenesis and promotes tumor progression [29, 30] . Under physiological conditions, PI3K/AKT signaling pathway is one of the important signal transduction pathways and plays a key role in inhibiting apoptosis and promoting proliferation by affecting the activation state of various downstream effector molecules [31] . Many factors could cause aberrant phosphorylation of PI3K/AKT/mTOR, such as interleukin-6 [32] . We further tested whether this mechanism is involved in the promotion of HCC by miRNA-873. Our data show that miRNA-873 can significantly phosphorylate PI3K/ AKT/mTOR and that inhibition of miRNA-873 can inactivate these two factors.
Conclusion
In summary, our study was the first to show that miRNA-873 exerts a tumor-accelerative function in HCC by regulating cell growth and metastasis. Additionally, miRNA-873 promoted HCC progression by repressing TSLC1. The potential mechanism might be the excessive phosphorylation of PI3K/AKT/mTOR as an effect of miRNA-873. These results suggest that miRNA-873 might be employed as a novel and effective therapeutic target for HCC in the future.
